砸20亿美元获国内企业授权 诺和诺德减重赛道再布局

新京报
25 Mar

诺和诺德对减重赛道的野心,不止于司美格鲁肽。3月24日晚间,港股上市公司联邦制药发布公告,与诺和诺德达成协议,后者以20亿美元的价格,获得在全球多个地区开发、制造、商业化联邦制药在研药物UBT251的权利。  UBT251的临床试验数据是吸引诺和诺德出手的关键,临床前肥胖/糖尿病肾病药效模型显示,UBT251对肾脏尿白蛋白等相关肾损伤标志物和组织病理的整体改善效果明显优于司美格鲁肽。不过,在减重...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10